Sorry, you need to enable JavaScript to visit this website.

Press Releases

Categories

Keywords

  • All Keywords

April 2018

March 2018

Resource Library

Press Kits

These downloadable files, including fact sheets about Pfizer and approved images or videos, are packages curated by the Global Media Relations team for use by professional journalists.

View Press Kits Details

Contact Pfizer Media Relations

Media Contacts

United States, Canada, and Latin America
+1 212.733.1226

Europe, Middle East, and Africa
+44-(0)845.300.8033

Asia Pacific
+65.918.732.47

Email
[email protected]

Though intended for professional media, these resources may also be interesting to patients, healthcare professionals, and investors. The media relations team is focused on responding to media inquiries. However, we want to ensure that customers, investors, and others receive the appropriate attention.

For patients or healthcare professionals with questions about Pfizer’s vaccines or medicines, please see our global list of medical information contacts.

For investors with questions about Pfizer’s efforts, please visit our contact page and select "Shareholder Services".

For all other non-media inquiries, please visit the contact us page to reach the appropriate Pfizer contact.

Featured Stories

Programs & Initiatives

Bridging the Gap: Community-Based Organizations Seek Trust, Tools and Funding to Advance Public Health

Community-based organizations (CBOs) are the cornerstone of community health—yet across the country they face substantial uncertainty, according to a new national survey supported by the Pfizer Multicultural Health Equity Collective (The Collective).

Science & Innovation

Pursuing the Next Breakthrough in Cancer Cachexia

Cachexia, a complex wasting syndrome, impacts an estimated 9 million people worldwide. Currently, there are no FDA-approved treatments targeting its underlying cause.

Science & Innovation

Brighter Together: How the Pharmaceutical Industry is Shining a Light on a Rare Cause of Heart Failure

Among the lesser known causes of heart failure is transthyretin amyloid cardiomyopathy (ATTR-CM). Early suspicion and diagnosis are crucial. That’s why Pfizer is working with other industry partners as part of the ASPIRE group, led by Amyloidosis Research Consortium (ARC), to accelerate earlier detection and diagnosis.